CTX-M-type β-lactamases affect community Escherichia coli treatment, Greece [1]
dc.creator | Pournaras, S. | en |
dc.creator | Ikonomidis, A. | en |
dc.creator | Sofianou, D. | en |
dc.creator | Tsakris, A. | en |
dc.creator | Maniatis, A. N. | en |
dc.date.accessioned | 2015-11-23T10:46:04Z | |
dc.date.available | 2015-11-23T10:46:04Z | |
dc.date.issued | 2004 | |
dc.identifier.issn | 10806040 | |
dc.identifier.uri | http://hdl.handle.net/11615/32461 | |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-2542539916&partnerID=40&md5=7e07e3f910f45e6a9afc691136dd8905 | |
dc.subject | amikacin | en |
dc.subject | beta lactam antibiotic | en |
dc.subject | beta lactamase | en |
dc.subject | carbapenem derivative | en |
dc.subject | cefotaxime | en |
dc.subject | cefoxitin | en |
dc.subject | ceftazidime | en |
dc.subject | cephalosporin derivative | en |
dc.subject | ciprofloxacin | en |
dc.subject | clavulanic acid | en |
dc.subject | clindamycin | en |
dc.subject | cotrimoxazole | en |
dc.subject | CTX M beta lactamase | en |
dc.subject | gentamicin | en |
dc.subject | penicillin derivative | en |
dc.subject | piperacillin plus tazobactam | en |
dc.subject | quinoline derived antiinfective agent | en |
dc.subject | tazobactam | en |
dc.subject | tetracycline | en |
dc.subject | tetracycline derivative | en |
dc.subject | unclassified drug | en |
dc.subject | antibiotic sensitivity | en |
dc.subject | antibiotic therapy | en |
dc.subject | bacterial gene | en |
dc.subject | communicable disease | en |
dc.subject | demography | en |
dc.subject | drug contraindication | en |
dc.subject | Enterobacteriaceae | en |
dc.subject | enzyme synthesis | en |
dc.subject | Escherichia coli | en |
dc.subject | Greece | en |
dc.subject | human | en |
dc.subject | letter | en |
dc.subject | minimum inhibitory concentration | en |
dc.subject | nonhuman | en |
dc.subject | plasmid | en |
dc.subject | polymerase chain reaction | en |
dc.subject | pulsed field gel electrophoresis | en |
dc.subject | risk factor | en |
dc.subject | treatment outcome | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | beta-Lactam Resistance | en |
dc.subject | beta-Lactamases | en |
dc.subject | Community-Acquired Infections | en |
dc.subject | DNA, Bacterial | en |
dc.subject | Escherichia coli Infections | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Microbial Sensitivity Tests | en |
dc.subject | Prospective Studies | en |
dc.title | CTX-M-type β-lactamases affect community Escherichia coli treatment, Greece [1] | en |
dc.type | journalArticle | en |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |